Mereo BioPharma Group plc
MREO · XNASCIK 1719714fmd_0CSQ8RQ1YG3EKRQ41YT8VJ9N80Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 25 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total revenues | 0 | 10 | 0 | 1 |
| Research and development | 29 | 17 | 21 | 18 |
| Operating income | (54) | (28) | (47) | (40) |
| Interest expense | 4 | 3 | 1 | 0 |
| Interest and investment income | 1 | 2 | 3 | 2 |
| Other non-operating income (expense) | 1 | (0) | 0 | 0 |
| Income before taxes | (43) | (30) | (43) | (42) |
| Income tax expense | (1) | (1) | 0 | 0 |
| Net income from continuing operations | (42) | (29) | (43) | (42) |
| Net income | (42) | (29) | (43) | (42) |